Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination

BMC Medicine

Marc JM Bonten⁴  Wouter J de Waal²  Léon Winkel¹  Marlies van Houten⁵  Nico G Hartwig³  Mariet Felderhof⁵  Marie-Josée J Mangen⁴  Patricia Bruijning-Verhagen⁴ 

[1] Department of Pediatrics, Kennemer Hospital, Postbus 417, Haarlem 2000 AK, The Netherlands;Department of Pediatrics, Diakonessen Hospital, Postbus 80250, Utrecht 3508 TG, The Netherlands;Department of Pediatrics, Sint-Franciscus Hospital, Postbus 10900, Rotterdam 3004 BA, The Netherlands;Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Huispostnummer STR.6.131, Postbus 85500, Utrecht 3508 GA, The Netherlands;Department of Pediatrics, Spaarne Hospital, Postbus 770, Hoofddorp 2130 AT, The Netherlands

关键词: Mortality;    Nosocomial infection;    Hospitalization;    Targeted prevention;    High-risk population;    Cost-utility;    Cost-effectiveness;    Rotavirus vaccination;   

Others  :  857082
DOI  :  10.1186/1741-7015-11-112

 received in 2012-10-05, accepted in 2013-04-09,  发布年份 2013

【 摘 要 】

Background

The cost-effectiveness of universal rotavirus (RV) vaccination is controversial in developed countries. As a result, RV vaccination programs do not currently exist in most European countries. Hospitalization is the main driver of RV disease costs, and prematurity, low birth weight (LBW) and underlying medical conditions have been associated with RV hospitalization and complications. We investigated the cost-effectiveness of targeted RV vaccination of high-risk infants and universal RV vaccination versus no vaccination.

Methods

Disease burden, mortality and healthcare costs of RV hospitalization for children with and without prematurity, LBW and congenital pathology were quantified in two hospital-based observational studies in the Netherlands. Cost-effectiveness analysis was based on an age-structured stochastic multi-cohort model of the Dutch population comparing universal RV vaccination and targeted vaccination of high-risk infants to no vaccination. The primary endpoint was the incremental cost-effectiveness ratio (ICER), with a threshold of €35,000/quality-adjusted life year (QALY) from the healthcare provider perspective. Sensitivity analyses included vaccine price and coverage, herd-immunity and QALY losses.

Results

A total of 936 children with RV infection were included. Prematurity, LBW and congenital pathology were associated with increased risks of RV hospitalization (relative risks (RR) ranging from 1.6 to 4.4), ICU admission (RR ranging from 4.2 to 7.9), prolonged hospital stay (1.5 to 3.0 excess days) and higher healthcare costs (€648 to €1,533 excess costs). Seven children succumbed due to RV complications, all belonging to the high-risk population. Targeted RV vaccination was highly cost-effective and potentially cost-saving from the healthcare provider perspective with ICERs below €20,000/QALY in all scenarios with total (undiscounted) annual healthcare costs between -€0.1 and €0.5 million/year. Results were most sensitive to mortality rates, but targeted vaccination remained highly cost-effective up to reductions of 90% compared to observed mortality. Universal RV vaccination was not considered cost-effective (mean ICER: €60,200/QALY) unless herd-immunity and caretaker QALY losses were included and vaccine prices were €60 at most (mean ICER: €21,309/QALY).

Conclusion

We recommend targeted RV vaccination for high-risk infants in developed countries.

【 授权许可】

   
2013 Bruijning-Verhagen et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Cortes JE, Curns AT, Tate JE, Cortese MM, Patel MM, Zhou F, Parashar UD: Rotavirus vaccine and health care utilization for diarrhea in U.S. children. N Engl J Med 2011, 365:1108-1117.
• [2]Richardson V, Parashar U, Patel M: Childhood diarrhea deaths after rotavirus vaccination in Mexico. N Engl J Med 2011, 365:772-773.
• [3]National Advisory Committee on Immunization (NACI): Updated statement on the use of rotavirus vaccines. Can Commun Dis Rep 2010, 36:4. Advisory Committee Statement (ACS)
• [4]Committee on Infectious Diseases: Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics 2009, 123:1412-1420.
• [5]Cortese MM, Parashar UD: Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009, 58:1-25.
• [6]Vesikari T, Van Damme P, Giaquinto C, Gray J, Mrukowicz J, Dagan R, Guarino A, Szajewska H, Usonis V: Expert Working Group, European Society for Paediatric Infectious Diseases, European Society for Paediatric Gastroenterology, Hepatology, and Nutrition: European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition, Evidence-Based Recommendations for Rotavirus Vaccination in Europe: Executive Summary. J Pediatr Gastroenterol Nutr 2008, 46:615-618.
• [7]WHO: Rotavirus Vaccines: an update. WHO Weekly epidemiological record 2009. Report No: 51–52
• [8]Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI: Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007, 119:684-697.
• [9]Jit M, Mangen MJ, Melliez H, Yazdanpanah Y, Bilcke J, Salo H, Edmunds WJ, Beutels P: An update to "The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe". Vaccine 2010, 28:7457-7459.
• [10]Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ: Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health 2011, 11:462. BioMed Central Full Text
• [11]Bilcke J, Beutels P: Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009, 27:281-297.
• [12]Patel MM: Rotavirus vaccination programmes. BMJ 2012, 345:e5286.
• [13]Le Saux N, Bettinger J, Halperin S, Vaudry W, Scheifele D: Hospital Acquired Rotavirus Infections: Substantial Disease Burden in Canadian Pediatric Hospitals. Florence, Italy: Excellence in Pediatrics; 2009.
• [14]Johansen K, Bennet R, Bondesson K, Eriksson M, Hedlund KO, De Verdier KK, Uhnoo I, Svensson L: Incidence and estimates of the disease burden of rotavirus in Sweden. Acta Paediatr Suppl 1999, 88:20-23.
• [15]Waisbourd-Zinman O, Ben-Ziony S, Solter E, Scherf E, Samra Z, Ashkenazi S: Hospitalizations for nosocomial rotavirus gastroenteritis in a tertiary pediatric center: A 4-year prospective study. Am J Infect Control 2009, 37:465-469.
• [16]Verhagen P, Moore D, Manges A, Quach C: Nosocomial rotavirus gastroenteritis in a Canadian paediatric hospital: incidence, disease burden and patients affected. J Hosp Infect 2011, 79:59-63.
• [17]Wildi-Runge S, Allemann S, Schaad U, Heininger U: A 4-year study on clinical characteristics of children hospitalized with rotavirus gastroenteritis. Eur J Pediatr 2009, 168:1343-1348.
• [18]Le Saux N, Bettinger JA, Halperin SA, Vaudry W, Scheifele DW: Substanital morbidity for hospitalized children with community acquired rotavirus infections: 2005–2007 IMPAct Surveillance in Canadian hospitals. Pediatr Infect Dis J 2010, 29:879-882.
• [19]Johansen K, Hedlund KO, Zweygberg-Wirgart B, Bennet R: Complications attributable to rotavirus-induced diarrhoea in a Swedish paediatric population: Report from an 11-year surveillance. Scand J Infect Dis 2008, 40:958-964.
• [20]Ford-Jones EL, Wang E, Petric M, Corey P, Moineddin R, Fearon M: Hospitalization for community-acquired, rotavirus-associated diarrhea: a prospective, longitudinal, population-based study during the seasonal outbreak, The Greater Toronto Area/Peel Region PRESI Study Group. Pediatric Rotavirus Epidemiology Study for Immunization. Arch Pediatr Adolesc Med 2000, 154:578-585.
• [21]Chang HG, Glass RI, Smith PF, Cicirello HG, Holman RC, Morse DL: Disease burden and risk factors for hospitalizations associated with rotavirus infection among children in New York State, 1989 through 2000. Pediatr Infect Dis J 2003, 22:808-814.
• [22]Dennehy PH, Cortese MM, Bégué RE, Jaeger JL, Roberts NE, Zhang R, Rhodes P, Gentsch J, Ward R, Bernstein DI, Vitek C, Bresee JS, Staat MA: A case–control study to determine risk factors for hospitalization for rotavirus gastroenteritis in U.S. children. Pediatr Infect Dis J 2006, 25:12.
• [23]Herruzo R, Omeñaca F, Garcia S, Diez J, Sanchez-Fauquier A: Identification of risk factors associated with nosocomial infection by rotavirus P4G2, in a neonatal unit of a tertiary-care hospital. Clin Microbiol Infect 2009, 15:280-285.
• [24]Newman RD, Grupp-Phelan J, Shay DK, Davis RL: Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics 1999, 103:E3.
• [25]Rotbart HA, Nelson WL, Glode MP, Triffon TC, Kogut SJ, Yolken RH, Hernandez JA, Levin MJ: Neonatal rotavirus-associated necrotizing enterocolitis: case control study and prospective surveillance during an outbreak. J Pediatr 1988, 112:87-93.
• [26]Sharma R, Garrison RD, Tepas JJ III, Mollitt DL, Pieper P, Hudak ML, Bradshaw JA, Stevens G, Premachandra BR: Rotavirus-associated necrotizing enterocolitis: an insight into a potentially preventable disease? J Pediatr Surg 2004, 39:453-457.
• [27]Boccia D, Stolfi I, Lana S, Moro ML: Nosocomial necrotising enterocolitis outbreaks: epidemiology and control measures. Eur J Pediatr 2001, 160:385-391.
• [28]Bagci S, Eis-Hubinger AM, Yassin AF, Simon A, Bartmann P, Franz AR, Mueller A: Clinical characteristics of viral intestinal infection in preterm and term neonates. Eur J Clin Microbiol Infect Dis 2010, 29:1079-1084.
• [29]Verboon-Maciolek MA, Truttmann AC, Groenendaal F, Skranes J, Dollner H, Hunt RW, Hayman M, Diepersloot RJ, van Loon AM, de Vries LS: Development of cystic periventricular leukomalacia in newborn infants after rotavirus infection. J Pediatr 2012, 160:165-168.
• [30]Desai R, Esposito DH, Lees C, Goodin K, Harris M, Blostein J, Parashar UD: Rotavirus-coded deaths in children, United States, 1999 to 2007. Pediatr Infect Dis J 2011, 30:986-988.
• [31]Parashar UD, Kilgore PE, Holman RC, Clarke MJ, Bresee JS, Glass RI: Diarrheal mortality in US infants: influence of birth weight on risk factors for death. Arch Pediatr Adolesc Med 1998, 152:47-51.
• [32]Mehal JM, Esposito DH, Holman RC, Tate JE, Callinan LS, Parashar UD: Risk factors for diarrhea-associated infant mortality in the United States, 2005 to 2007. Pediatr Infect Dis J 2012, 31:717-721.
• [33]Bruijning-Verhagen P, Sankatsing V, Kunst A, van den Born C, Bleeker E, Thijsen S, Ijzerman EP, van der Velden VH, Bonten MJ: Rotavirus related hospitalizations are responsible for high seasonal peaks in all-cause pediatric hospitalizations. Pediatr Infect Dis J 2012, 31:e244-e249.
• [34]Feudtner C, Hays RM, Haynes G, Geyer JR, Neff JM, Koepsell TD: Deaths attributed to pediatric complex chronic conditions: national trends and implications for supportive care services. Pediatrics 2001, 107:e99.
• [35]Simon TD, Berry J, Feudtner C, Stone BL, Sheng X, Bratton SL, Dean JM, Srivastava R: Children with complex chronic conditions in inpatient hospital settings in the United States. Pediatrics 2010, 126:647-655.
• [36]Berry JG, Hall DE, Kuo DZ, Cohen E, Agrawal R, Feudtner C, Hall M, Kueser J, Kaplan W, Neff J: Hospital utilization and characteristics of patients experiencing recurrent readmissions within children's hospitals. JAMA 2011, 305:682-690.
• [37]Eurocat Noord Nederland: Algemene cijfers tabel 1,2,3 en 4. Eurocat Nederland 2011. Available from: http://www.rug.nl/umcg/faculteit/disciplinegroepen/MedischeGenetica/Eurocat/tabellen webcite; Accessed: 1 April 2012
• [38]Stichting Perinatale Registratie Nederland (PRN): Perinatale Zorg in Nederland. 2008, 1-149. Available from: http://www.perinatreg.nl/jaarboeken_zorg_in_nederland?noCache=365;1332865370 webcite
• [39]Hakkart-van Roijen L, Tan S, Bouwmans C: Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. [Methods and standard cost prices for economic evaluations in healthcare]. Version 2010. Diemen, The Netherlands: College van Zorgverzekeringen; 2011.
• [40]Indeling tarieflijst instellingen 2011 [Charges for healthcare institutions 2011]. Nederlandse Zorgautoriteit: Bijlage 2; 2011. Report No.: BR_CU_2015
• [41]Hubben G, Bootsma M, Luteijn M, Glynn D, Bishai D, Bonten M, Postma M: Modelling the costs and effects of selective and universal hospital admission screening for methicillin-resistant Staphylococcus aureus. PLoS One 2011, 6:e14783.
• [42]Lumley T: Analysis of complex survey samples. Journal of Statistical Software 2004, 9:1-19.
• [43]Thompson SG, Barber JA: How should cost data in pragmatic randomised trials be analysed? BMJ 2000, 320:1197-1200.
• [44]Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine MMWR Morb Mortal Wkly Rep 2011, 59:687-688.
• [45]Mangen MJ, van Duynhoven YT, Vennema H, Van PW, Havelaar AH, De Melker HE: Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine 2010, 28:2624-2635.
• [46]Zickafoose JS, Benneyworth BD, Riebschleger MP, Espinosa CM, Davis MM: Hospitalizations for intussusception before and after the reintroduction of rotavirus vaccine in the United States. Arch Pediatr Adolesc Med 2012, 166:350-355.
• [47]Tate JE, Steele AD, Bines JE, Zuber PL, Parashar UD: Research priorities regarding rotavirus vaccine and intussusception: a meeting summary. Vaccine 2012, 30:A179-A184.
• [48]Yen C, Tate JE, Steiner CA, Cortese MM, Patel MM, Parashar UD: Trends in intussusception hospitalizations among US infants before and after implementation of the rotavirus vaccination program, 2000–2009. J Infect Dis 2012, 206:41-48.
• [49]Van der Wielen M, Van Damme P: Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial. Eur J Clin Microbiol Infect Dis 2008, 27:495-501.
• [50]Goveia MG, Rodriguez ZM, Dallas MJ, Itzler RF, Boslego JW, Heaton PM, DiNubile MJ: REST Study Team: Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J 2007, 26:1099-1104.
• [51]Tilson L, Jit M, Schmitz S, Walsh C, Garvey P, McKeown P, Barry M: Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine 2011, 29:7463-7473.
• [52]Friesema I, Lugnér A, van Duynhoven YT: GEops Working Group: Costs of gastroenteritis in the Netherlands, with special attention for severe cases. Eur J Clin Microbiol Infect Dis 2012, 31:1895-1900.
• [53]Desai R, Curns AT, Steiner CA, Tate JE, Patel MM, Parashar UD: All-cause gastroenteritis and rotavirus-coded hospitalizations among US children, 2000–2009. Clin Infect Dis 2012, 55:e28-e34.
• [54]Pitzer VE, Atkins KE, de Blasio BF, Van ET, Atchison CJ, Harris JP, Shim E, Galvani AP, Edmunds WJ, Viboud C, Patel MM, Grenfell BT, Parashar UD, Lopman BA: Direct and indirect effects of rotavirus vaccination: comparing predictions from transmission dynamic models. PLoS One 2012, 7:e42320.
• [55]Centraal Bureau voor de Statistiek: Bevolking; Kerncijfers. Available from: http://statline.cbs.nl webcite; Accessed: 18 October 2011
• [56]de Wit MA, Koopmans MP, Kortbeek LM, Wannet WJ, Vinje J, van Leusden F, Bartelds AI, van Duynhoven YT: Sensor, a population-based cohort study on gastroenteritis in the Netherlands: incidence and etiology. Am J Epidemiol 2001, 154:666-674.
• [57]Fang AY, Tingay DG: Early observations in the use of oral rotavirus vaccination in infants with functional short gut syndrome. J Paediatr Child Health 2012, 48:512-516.
• [58]Vesikari T, Itzler R, Karvonen A, Korhonen T, Van DP, Behre U, Bona G, Gothefors L, Heaton PM, Dallas M, Goveia MG: RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 2009, 28:345-351.
• [59]Vesikari T, Karvonen A, Ferrante SA, Ciarlet M: Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur J Pediatr 2010, 169:1379-1386.
• [60]Vesikari T, Dennehy P, Matson D, Itzler R, Dallas M, Goveia M, DiNubile M, Heaton P, Lawrence J, Ciarlet M: Efficacy of Rotateq®, the pentavalent rotavirus vaccine, between doses: potential benefits of early protection [abstract]. Arch Dis Child 2008, 93:pw 70.
• [61]Brisson M, Sénécal M, Drolet M, Mansi JA: Health-related quality of life lost to rotavirus-associated gastroenteritis in children and their parents: a Canadian prospective study. Pediatr Infect Dis J 2010, 29:73-75.
• [62]Brandhof WE, Wit GA, Wit MA, Duynhoven YT: Costs of gastroenteritis in the Netherlands. Epidemiol Infect 2004, 132:211-221.
• [63]de Wit MA, Koopmans MP, Kortbeek LM, van Leeuwen NJ, Bartelds AI, van Duynhoven YT: Gastroenteritis in sentinel general practices, The Netherlands. Emerg Infect Dis 2001, 7:82-91.
• [64]Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A: Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370:1757-1763.
• [65]Vesikari T, Dennehy P, Matson D: Efficay of Pentavalent Rotavirus Vaccine, RotaTeq, between Doses: Potential Benefits of Early Protection. Istanbul, Turkey: 8th International Rotavirus Symposium; 2008.
• [66]Lopman BA, Curns AT, Yen C, Parashar UD: Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011, 204:980-986.
• [67]Payne DC, Staat MA, Edwards KM, Szilagyi PG, Weinberg GA, Hall CB, Chappell J, Curns AT, Wikswo M, Tate JE, Lopman BA, Parashar UD: New Vaccine Surveillance Network (NVSN): Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US counties, 2006–2009. Clin Infect Dis 2011, 53:245-253.
• [68]Macartney KK, Porwal M, Dalton D, Cripps T, Maldigri T, Isaacs D, Kesson A: Decline in rotavirus hospitalisations following introduction of Australia's national rotavirus immunisation programme. J Paediatr Child Health 2011, 47:266-270.
• [69]Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, Akikusa JD, Kelly JJ, Kirkwood CD: Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J 2011, 30:S25-S29.
• [70]Raes M, Strens D, Vergison A, Verghote M, Standaert B: Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J 2011, 30:e120-e125.
• [71]Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M: Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J 2010, 29:957-963.
• [72]Iturriza-Gómara M, Dallman T, Bányai K, Böttiger B, Buesa J, Diedrich S, Fiore L, Johansen K, Koopmans M, Korsun N, Koukou D, Kroneman A, László B, Lappalainen M, Maunula L, Marques AM, Matthijnssens J, Midgley S, Mladenova Z, Nawaz S, Poljsak-Prijatelj M, Pothier P, Ruggeri FM, Sanchez-Fauquier A, Steyer A, Sidaraviciute-Ivaskeviciene I, Syriopoulou V, Tran AN, Usonis V, VAN Ranst M: Rotavirus genotypes co-circulating in Europe between 2006 and 2009 as determined by EuroRotaNet, a pan-European collaborative strain surveillance network. Epidemiol Infect 2011, 139:895-909.
• [73]Zeller M, Rahman M, Heylen E, De CS, De Vos S, Arijs I, Novo L, Verstappen N, Van Ranst M, Matthijnssens J: Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010, 28:7507-7513.
• [74]Friesema IH, de Boer RF, Duizer E, Kortbeek LM, Notermans DW, Norbruis OF, Bezemer DD, van Heerbeek H, van Andel RN, van Enk JG, Fraaij PL, Koopmans MP, Kooistra-Smid AM, van Duynhoven YT: Etiology of acute gastroenteritis in children requiring hospitalization in the Netherlands. Eur J Clin Microbiol Infect Dis 2011, 31:405-415.
• [75]Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL: WHO Guide to Cost-effectiveness Analysis. Geneva: World Health Organization; 2003.
• [76]Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992, 146:473-481.
• [77]Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B: Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004, 7:518-528.
• [78]Koch J, Wiese-Posselt M: Epidemiology of rotavirus infections in children less than 5 years of age: Germany, 2001–2008. Pediatr Infect Dis J 2011, 30:112-117.
• [79]Harris JP, Jit M, Cooper D, Edmunds WJ: Evaluating rotavirus vaccination in England and Wales part I, estimating the burden of disease. Vaccine 2007, 25:3962-3970.
• [80]Vesikari T, Rautanen T, Von Bonsdorff CH: Rotavirus gastroenteritis in Finland: burden of disease and epidemiological features. Acta Paediatr Suppl 1999, 88:24-30.
• [81]de Wit MA, Koopmans MP, van der Blij JF, van Duynhoven YT: Hospital admissons for rotavirus infection in the Netherlands. Clin Infect Dis 2000, 31:698-704.
• [82]van Pelt W, Notermans D, Mevius D, Vennema H, Koopmans M, van Duynhoven Y: Trends in gastro-enteritis van 1996–2006: Verdere toename van ziekenhuisopnames, maar stabiliserende sterfte. Infectieziektenbulletin 2008, 19:24-31.
• [83]Parashar UD, Holman RC, Clarke MJ, Bresee JS, Glass RI: Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code. J Infect Dis 1998, 177:13-17.
• [84]Hsu VP, Staat MA, Roberts N, Thieman C, Bernstein DI, Bresee J, Glass RI, Parashar UD: Use of active surveillance to validate international classification of diseases code estimates of rotavirus hospitalizations in children. Pediatrics 2005, 115:78-82.
• [85]Matson DO, Staat MA, Azimi P, Itzler R, Bernstein DI, Ward RL, Dahiya R, DiNubile MJ, Barnes-Eley M, Berke T: Burden of rotavirus hospitalisations in young children in three paediatric hospitals in the United States determined by active surveillance compared to standard indirect methods. J Paediatr Child Health 2012, 48:698-704.
• [86]Belongia EA, Irving SA, Shui IM, Kulldorff M, Lewis E, Yin R, Lieu TA, Weintraub E, Yih WK, Li R, Baggs J: Vaccine Safety Datalink Investigation Group: Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr Infect Dis J 2010, 29:1-5.
• [87]Buttery JP, Danchin MH, Lee KJ, Carlin JB, McIntyre PB, Elliott EJ, Booy R, Bines JE: PAEDS/APSU Study Group: Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011, 29:3061-3066.
• [88]Geier DA, King PG, Sykes LK, Geier MR: The temporal relationship between RotaTeq immunization and intussusception adverse events in the Vaccine Adverse Event Reporting System (VAERS). Med Sci Monit 2012, 18:H12-H17.
• [89]Haber P, Patel M, Izurieta HS, Baggs J, Gargiullo P, Weintraub E, Cortese M, Braun MM, Belongia EA, Miller E, Ball R, Iskander J, Parashar UD: Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 2008, 121:1206-1212.
• [90]Loughlin J, Mast TC, Doherty MC, Wang FT, Wong J, Seeger JD: Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine. Pediatr Infect Dis J 2012, 31:292-296.
• [91]Patel MM, Lopez-Collada VR, Bulhoes MM, de Oliveira LH, Bautista MA, Flannery B, Esparza-Aguilar M, Montenegro Renoiner EI, Luna-Cruz ME, Sato HK, Hernández-Hernández Ldel C, Toledo-Cortina G, Cerón-Rodríguez M, Osnaya-Romero N, Martínez-Alcazar M, Aguinaga-Villasenor RG, Plascencia-Hernández A, Fojaco-González F, Hernández-Peredo Rezk G, Gutierrez-Ramírez SF, Dorame-Castillo R, Tinajero-Pizano R, Mercado-Villegas B, Barbosa MR, Maluf EM, Ferreira LB, de Carvalho FM, dos Santos AR, Cesar ED, de Oliveira ME: Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011, 364:2283-2292.
• [92]Shui IM, Baggs J, Patel M, Parashar UD, Rett M, Belongia EA, Hambidge SJ, Glanz JM, Klein NP, Weintraub E: Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA 2012, 307:598-604.
• [93]Velazquez FR, Colindres RE, Grajales C, Hernandez MT, Mercadillo MG, Torres FJ, Cervantes-Apolinar M, DeAntonio-Suarez R, Ortega-Barria E, Blum M, Breuer T, Verstraeten T: Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J 2012, 31:736-744.
• [94]Omeñaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran P, Smolenov IV, Han HH: ROTA-054 Study Group: Safety, reactogenicity and immunogenicity of human rotavirus vaccine in preterm European infants: a randomized phase IIIb study. Pediatr Infect Dis J 2012, 31:487-493.